LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
36 hedge funds and large institutions have $131M invested in LogicBio Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$78.1M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$11M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11M |
| 4 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
+$11M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$8.46M |
Top Sellers
LOGC Hedge Fund Activity: Q4 2018 in Review
36 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q4 2018, worth a combined $131M.
Buyers outnumbered sellers: 36 funds opened new LOGC positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $78.1M.
- 36 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $131M of LogicBio Therapeutics, Inc. Common Stock stock for Q4 2018.
- 36 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q4 2018 and 0 closed out, a net change of +36 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q4 2018 was OrbiMed, an estimated $78.1M added.
Based on aggregated 13F filings for Q4 2018.